Kayexalate (Sodium Polystyrene Sulfonate)

Kayexalate is used to manage elevated potassium levels in conditions affecting electrolyte balance.

• Hyperkalemia: reduces serum potassium concentrations to safer levels.
• Chronic kidney disease‑associated hyperkalemia: assists in controlling potassium accumulation in patients with impaired renal excretion.
• Acute potassium poisoning: facilitates removal of excess potassium from the gastrointestinal tract.
• Pre‑dialysis potassium management: helps lower potassium before dialysis sessions.
• Post‑transplant hyperkalemia: used to control potassium in kidney transplant recipients.

• Sodium Polystyrene Sulfonate is a non‑absorbable polymeric resin that exchanges sodium ions for potassium ions within the gastrointestinal lumen. The resin binds potassium in the colon and small intestine, forming an insoluble complex that is eliminated with feces, thereby decreasing the amount of potassium reabsorbed into the bloodstream. The exchange process is driven by concentration gradients and occurs throughout the intestinal tract, providing a continuous reduction of systemic potassium as the bound resin passes through.

Sodium Polystyrene Sulfonate may cause gastrointestinal and electrolyte related adverse reactions.

Common Side Effects

• Nausea: mild stomach upset may occur.
• Vomiting: occasional emesis reported.
• Constipation: reduced bowel movements are frequent.
• Abdominal discomfort: cramps or pain in the abdomen.
• Diarrhea: loose stools may develop.
• Taste alteration: some patients notice a metallic taste.

Serious or Rare Side Effects

• Intestinal necrosis: rare but severe tissue death in the gut.
• Colonic perforation: possible tearing of the colon wall.
• Severe electrolyte disturbances: including hypokalemia or hypernatremia.
• Anaphylactic reaction: rare systemic allergic response.

Before prescribing Kayexalate, clinicians should consider several safety precautions to minimize risks.

• Renal impairment: monitor serum potassium and sodium levels closely.
• Bowel obstruction: avoid use in patients with known gastrointestinal blockage.
• Severe constipation: use with caution and consider laxatives if needed.
• Sorbitol‑containing laxatives: do not co‑administer due to risk of intestinal injury.
• Pregnancy: category B; use only when potential benefit justifies potential risk.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Kayexalate can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Sorbitol co‑administration: increases risk of intestinal necrosis.
• Potassium‑sparing diuretics (e.g., spironolactone): may reduce the resin’s potassium‑lowering effect.
• Oral potassium supplements: concurrent use can blunt therapeutic benefit.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may interfere with resin binding capacity.
• Lithium therapy: resin may alter lithium absorption, requiring level monitoring.
• Digoxin: electrolyte shifts from potassium removal may affect digoxin toxicity risk.